Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIM-725: Tavilermide in Dry Eye
NCT01960010Phase 3Completed
- Sponsor
- Mimetogen Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tavilermide in dry eye syndrome (DED), sponsored by Mimetogen Pharmaceuticals. Started Oct 2013; status: completed.
02
Drugs
tavilermide
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01960010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960010.